Literature DB >> 25109398

Effects of D-allose in combination with docetaxel in human head and neck cancer cells.

Kanako Indo1, Hiroshi Hoshikawa1, Kazuyo Kamitori2, Fuminori Yamaguchi2, Terusige Mori1, Masaaki Tokuda2, Nozomu Mori1.   

Abstract

In this study we investigated the combined effects of docetaxel and d-allose in HSC3 human oral carcinoma cells. The dose enhancement ratios at the 25% survival level were 1.3 and 1.71 for combined treatment with 10 or 25 mM D-allose, respectively. Apoptosis was significantly increased by addition of D-allose. Additionally, a synchronous increase in the G(2)/M-phase population was observed after docetaxel plus D-allose treatment. In vivo experiments revealed that docetaxel plus D-allose was more effective than either agent alone. Thus, D-allose enhanced the anticancer effects of docetaxel, and combined treatment may be useful to achieve clinical efficacy with reduced toxicity.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25109398     DOI： 10.3892/ijo.2014.2590

Source DB:  PubMed          Journal:  Int J Oncol        ISSN： 1019-6439            Impact factor:   5.650


  7 in total

1.  CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.

Authors:  Ting Wang; Qingyuan Zhan; Xiaodong Peng; Zhimin Qiu; Tiantian Zhao
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

2.  Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.

Authors:  Yoichiro Tohi; Rikiya Taoka; Xia Zhang; Yuki Matsuoka; Akihide Yoshihara; Emi Ibuki; Reiji Haba; Kazuya Akimitsu; Ken Izumori; Yoshiyuki Kakehi; Mikio Sugimoto
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

Review 3.  The Role of the Thioredoxin Detoxification System in Cancer Progression and Resistance.

Authors:  Mirna Jovanović; Ana Podolski-Renić; Mikhail Krasavin; Milica Pešić
Journal:  Front Mol Biosci       Date:  2022-05-19

4.  Both Ser361 phosphorylation and the C-arrestin domain of thioredoxin interacting protein are important for cell cycle blockade at the G1/S checkpoint.

Authors:  Kazuyo Kamitori; Fuminori Yamaguchi; Youyi Dong; Akram Hossain; Ayako Katagi; Chisato Noguchi; Yuko Hirata; Ikuko Tsukamoto; Naoya Hatano; Masaaki Tokuda
Journal:  FEBS Open Bio       Date:  2018-10-01       Impact factor: 2.693

5.  Combined treatment with D-allose, docetaxel and radiation inhibits the tumor growth in an in vivo model of head and neck cancer.

Authors:  Hiroshi Hoshikawa; Kazuyo Kamitori; Kanako Indo; Terushige Mori; Mizuna Kamata; Tomoko Takahashi; Masaaki Tokuda
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

Review 6.  ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.

Authors:  Gan Huang; Shu-Ting Pan
Journal:  Oxid Med Cell Longev       Date:  2020-07-22       Impact factor: 6.543

7.  D-allose alleviates ischemia/reperfusion (I/R) injury in skin flap via MKP-1.

Authors:  Jihui Ju; Ruixing Hou; Ping Zhang
Journal:  Mol Med       Date:  2020-02-11       Impact factor: 6.354
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.